10-Q
Quarterly Report
20/20 BIOLABS, INC.
AIDX
NASDAQ
CIK: 1139685
File #: 001-43128
Balance Sheet
54 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
Current assets: | ||
Cash and cash equivalents | 4,219,099 | 1,025,987 |
Accounts receivable, net | 201,481 | 199,954 |
Inventory | 104,523 | 116,217 |
Prepaid expenses and other current assets | 175,174 | 128,975 |
Total current assets | 4,700,277 | 1,471,133 |
License agreement, net | 265,518 | 271,143 |
Property and equipment, net | 45,187 | 56,677 |
Intangible asset, net | 206,801 | 202,264 |
Right-of-use assets, net | 562,507 | 605,289 |
Deferred financing costs | — | 1,507,794 |
Other assets | 23,057 | 23,057 |
Total assets | 5,803,347 | 4,137,357 |
Current liabilities: | ||
Accounts payable | 980,486 | 868,545 |
Accrued liabilities | 598,335 | 785,784 |
Accrued dividends — Series E convertible preferred stock | 54,192 | — |
Series E Convertible Preferred Stock | 54,192 | — |
Deferred revenue | 450,667 | 414,871 |
Derivative liability – current | — | 143,382 |
Convertible note | 306,716 | 74,611 |
Operating lease liability – current | 189,649 | 175,948 |
Total current liabilities | 2,580,045 | 2,463,141 |
Long-term liabilities: | ||
Convertible notes payable, net | — | 619,355 |
Secured Convertible Promissory Notes | 570,000 | — |
Deferred revenue – long-term | 37,055 | 41,816 |
Derivative liabilities – long-term | — | 543,545 |
Operating lease liability – long term | 429,122 | 488,725 |
Total long-term liabilities | 466,177 | 1,693,441 |
Total liabilities | 3,046,222 | 4,156,582 |
Contingently redeemable convertible preferred stock: | ||
Series E Convertible Preferred Stock | 204,239 | — |
Stockholders’ equity (deficit): | ||
Series D | — | 1,016 |
Series C | — | 12,040 |
Series B | — | 14,715 |
Series A-2 | — | 4,424 |
Series A-1 | — | 6,515 |
Series A | — | 8,464 |
Common stock, $0.01 par value; 50,000,000 authorized; 10,442,960 and 5,442,249 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 104,430 | 54,422 |
Additional paid-in capital | 37,870,511 | 33,126,398 |
Accumulated deficit | (35,422,055) | (33,247,219) |
Total stockholders’ (deficit) equity | 2,552,886 | (19,225) |
Series D - Preferred Stock | — | 1,016 |
Series C - Preferred Stock | — | 12,040 |
Series B - Preferred Stock | — | 14,715 |
Series A-2 - Preferred Stock | — | 4,424 |
Series A-1 - Preferred Stock | — | 6,515 |
Series A - Preferred Stock | — | 8,464 |
Common Stock | 104,430 | 54,422 |
Additional Paid-in Capital | 37,870,511 | 33,126,398 |
Accumulated Deficit | (35,422,055) | (33,247,219) |
Total liabilities, contingently redeemable preferred stock and stockholders’ equity | 5,803,347 | 4,137,357 |